149 related articles for article (PubMed ID: 3550616)
1. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
4. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
[TBL] [Abstract][Full Text] [Related]
6. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
7. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
9. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sampi K; Honda T; Hayashi Y; Hattori M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
[TBL] [Abstract][Full Text] [Related]
10. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
[TBL] [Abstract][Full Text] [Related]
11. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of aclacinomycin A.
Van Echo DA; Whitacre MY; Aisner J; Applefeld MM; Wiernik PH
Cancer Treat Rep; 1982 May; 66(5):1127-32. PubMed ID: 6952961
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of acute leukemia in the adult. Role of anthracyclines].
Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
[TBL] [Abstract][Full Text] [Related]
14. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
[TBL] [Abstract][Full Text] [Related]
15. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
16. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
17. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
[TBL] [Abstract][Full Text] [Related]
19. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
[TBL] [Abstract][Full Text] [Related]
20. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
